Form 8-K - Current report:
SEC Accession No. 0001193125-25-145741
Filing Date
2025-06-24
Accepted
2025-06-24 16:15:15
Documents
14
Period of Report
2025-06-20
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d871650d8k.htm   iXBRL 8-K 42730
2 EX-10.1 d871650dex101.htm EX-10.1 193010
6 GRAPHIC g871650g0520020555046.jpg GRAPHIC 2721
  Complete submission text file 0001193125-25-145741.txt   397176

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20250620.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20250620_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20250620_pre.xml EX-101.PRE 11266
17 EXTRACTED XBRL INSTANCE DOCUMENT d871650d8k_htm.xml XML 3670
Mailing Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453
Business Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

EIN.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 251069384
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)